IMUX Immunic Therapeutics: שווי חברה להכנסות

Immunic, Inc. is developing advanced oral molecules for the therapy of severe autoimmune pathologies, leveraging robust scientific and technological potential. The EV-to-revenue ratio reflects market expectations, with the current level standing at 0.00. The company's strategy is based on replacing injections with convenient tablets for the treatment of sclerosis. The production of pilot drug batches is carried out through reliable contract partners with automated logistics.
Immunic Therapeutics - פילוחים אנליטיים ומדדי מפתח (IMUX)

Immunic, Inc. (IMUX) is scaling its pipeline of selective drugs against multiple sclerosis, aiming for dominance in the targeted immunotherapy segment. The current value of 0.00 reflects the enterprise value to sales ratio, where the Enterprise Value to Sales extremes on this chart indicate potential entry points or risks of revenue stagnation during market downturns.